This Evidence Watch article reviews a 2026 systematic evidence update on adolescent substance use treatment. The review found that family-based therapy, CBT, motivational approaches, and multicomponent behavioral care remain the best-supported outpatient options, while cannabis-specific and opioid-specific adolescent evidence remains limited. The main caution is that the paper updates the evidence base rather than testing a new intervention, so its strongest value is clinical framing, not a new treatment breakthrough.
“We need to get educated”: lessons from physicians certifying cannabis as an alternative to opioids in the Illinois Opioid Alternative Patient Program.
A survey of Illinois physicians participating in the state’s Opioid Alternative Patient Program revealed that cannabis as opioid alternative physician education remains a critical need. Even early adopter clinicians emphasized educational gaps as a primary implementation barrier, highlighting broader challenges in integrating cannabis medicine into clinical practice.
The Effects of Extended Cannabis Abstinence in Comorbid Posttraumatic Stress Disorder and Cannabis Use Disorder.
A clinical study examined cannabis abstinence effects in PTSD patients with cannabis use disorder, finding measurable changes during extended cessation periods. While the research addresses an important dual-diagnosis scenario, the specific nature and clinical implications of these effects require full study review to guide treatment decisions.
Enhancing the endocannabinoid system to treat residual disease in relapse-free multiple sclerosis.
A new consensus from Italian neurologists proposes enhancing the endocannabinoid system multiple sclerosis treatment approach for patients with relapse-free disease. The algorithm combines cannabinoid agents with lifestyle interventions to address residual symptoms like spasticity in MS patients on high-efficacy therapies.
Letter by Wu et al Regarding Article, “G Protein-Coupled Receptor Kinase 3 Exacerbates Diabetic Heart Injuries Through Direct Phosphorylation of Cannabinoid Receptor 2 in Humans and Mice”.
Laboratory research published in Circulation identifies how diabetes may worsen heart complications through disruption of cannabinoid receptor 2 function. This diabetic heart disease cannabinoid receptor research provides mechanistic insights but requires clinical validation before therapeutic applications.
Combined Impact of Cannabinoids and Cocaine on Outcomes of Trauma Patients.
A large retrospective study of trauma patients found no significant difference in hospital mortality between those testing positive for cannabinoids cocaine trauma mortality outcomes versus cannabinoids alone. While this challenges assumptions about polysubstance toxicity, the findings require careful interpretation given study limitations.
Outpacing Emerging Drug Threats: Validation of ToxBox Kits That Automate LC-MS/MS Analyses.
Automated LC-MS/MS testing platforms successfully validated cannabinoid detection alongside other substances in public health overdose surveillance programs. This technology enables real-time monitoring of polysubstance use patterns involving cannabis, though clinical interpretation requires distinguishing coincidental use from causal contribution. The validation represents a technical advance in drug surveillance capabilities without establishing clinical outcomes or cannabis-overdose causation.
Drugs detected in suspected pediatric exposures: a 5-year review.
A 5-year hospital study found pediatric cannabis exposure emergency department detection patterns showing cannabis metabolites among the most frequently identified compounds in children presenting with suspected toxic ingestions. This surveillance data helps inform clinical testing strategies while highlighting the importance of secure household cannabis storage practices.
Therapeutic potential and pharmacological mechanisms of cannabinoids in alleviating chemotherapy-induced organ toxicity and adverse effects.
A comprehensive review examines how cannabinoids chemotherapy organ protection mechanisms could address treatment-limiting toxicities. While theoretical evidence suggests promise through anti-inflammatory and antioxidant pathways, clinical validation remains necessary before therapeutic recommendations.
Cannabinoid Effects of Metamizol/Dipyrone: A Possible Second Life in Pediatric Anesthesia for a Vintage Drug.
Recent research demonstrates that metamizol/dipyrone exhibits cannabinoid effects in pediatric anesthesia applications, revealing endocannabinoid system interactions. This study provides mechanistic insights into how this vintage analgesic may achieve therapeutic effects through cannabinoid pathway modulation. Understanding metamizol cannabinoid effects could inform future pediatric pain management strategies.